Renal/Urology · PANCE / PANRE

Bladder Cancer

Written & clinically reviewed by Ryan Busch, PA-C · Updated August 2026 · Report an error

Urothelial carcinoma presenting with painless hematuria; strongly linked to smoking.

Also known as: bladder cancer, urothelial carcinoma, transitional cell carcinoma, TCC

Overview

Malignancy arising from the urothelium lining the bladder. Urothelial carcinoma (formerly transitional cell carcinoma) accounts for >90% of cases in developed countries. Categorized as non-muscle-invasive bladder cancer (NMIBC; Ta, T1, Tis) — 75% at diagnosis — or muscle-invasive bladder cancer (MIBC; T2+).

Epidemiology

~83,000 new cases and ~17,000 deaths annually in the US. Fourth most common cancer in men. Male:female ratio ~3:1. Median age at diagnosis 73 years. Most cases occur in current or former smokers.

Try two board-style Bladder Cancer questions

Real questions from the FirstPassPA bank, with the full explanation. Pick an answer — no signup, no email.

Question 1RenalMedium
A 68-year-old man presents after a single episode of painless gross hematuria. He denies dysuria, flank pain, fever, or trauma and takes no anticoagulants. Vital signs are normal and the physical examination is unremarkable. Urinalysis shows more than 100 red blood cells per high-power field with no casts, no proteinuria, no pyuria, and negative nitrites. Cystoscopy and CT urography are planned. Which of the following is the strongest risk factor for the suspected diagnosis?
  • ACoffee consumption
  • BCigarette smoking
  • CRecurrent cystitis
  • DFrequent NSAID use
Reveal answer & full explanation
Correct answer: B — Cigarette smoking
  • ACoffee consumption
  • BCigarette smoking✓
  • CRecurrent cystitis
  • DFrequent NSAID use

Why Cigarette smoking is correct

  • Painless gross hematuria in an older adult with no infection, casts, or proteinuria is urothelial (bladder) carcinoma until proven otherwise, prompting cystoscopy and CT urography.
  • Cigarette smoking is the single strongest and most prevalent modifiable risk factor, accounting for roughly half of all urothelial bladder cancers through excreted aromatic-amine and polycyclic-hydrocarbon carcinogens.
  • Risk is dose-dependent and declines but does not normalize after cessation.

Why the others are wrong

  • Coffee consumption — Any epidemiologic association is weak and largely confounded by smoking; it is not an established strong risk factor (weak-association trap).
  • Recurrent cystitis — Chronic bladder inflammation predisposes mainly to squamous cell carcinoma and is a far weaker contributor than smoking to the urothelial cancer suspected here (confused-with-subtype trap).
  • Frequent NSAID use — Historic phenacetin-containing analgesics were linked to urothelial cancer, but routine modern NSAID use is not a strong risk factor (anchoring on an outdated analgesic association).
Question 2RenalEasy
A 35-year-old man presents with painless total hematuria without clots. He smokes and works in a rubber manufacturing plant. Urinalysis confirms RBCs with no casts. Urine cytology shows atypical cells. Which is the most likely diagnosis?
  • ABenign prostatic hyperplasia
  • BBladder cancer
  • CNephrolithiasis
  • DGlomerulonephritis
Reveal answer & full explanation
Correct answer: B — Bladder cancer
  • ABenign prostatic hyperplasia
  • BBladder cancer✓
  • CNephrolithiasis
  • DGlomerulonephritis

Why Bladder cancer is correct

  • Painless hematuria in a smoker with occupational chemical exposure (aniline dyes, rubber manufacturing, aromatic amines) is bladder cancer until proven otherwise
  • Atypical urine cytology supports urothelial malignancy
  • Cystoscopy is the gold standard for diagnosis

Why the others are wrong

  • Benign prostatic hyperplasia — associated with obstructive symptoms (hesitancy, weak stream, nocturia) rather than painless total hematuria and atypical cytology
  • Nephrolithiasis — kidney stones cause painful hematuria, not the painless variety seen here
  • Glomerulonephritis — causes RBC casts on urinalysis; this patient has no casts and has risk factors strongly pointing to urothelial malignancy

Additional high-yield points

  • Risk factors for bladder cancer: smoking (strongest risk factor), chemical exposures (aniline dyes, rubber manufacturing, aromatic amines), cyclophosphamide, and schistosomiasis
🔒 Free preview limit reached

Keep reading — start your free trial

You've read your 2 free diagnosis previews. Create your free account to unlock the full Bladder Cancer outline — plus all 514 diagnoses, 6,500+ board-style questions, flashcards, and an AI tutor. Your 7-day free trial includes everything, and there's no credit card required.

Start your 7-day free trial → Sign in
Free to start · No credit card · Cancel anytime

Risk factors

  • Tobacco smoking (single greatest risk factor; 3-4× risk; accounts for ~50% of cases)
  • Occupational exposure: aromatic amines (dyes, rubber, leather, painters, hairdressers), polycyclic aromatic hydrocarbons
  • Chronic bladder inflammation: indwelling catheter, recurrent UTI, schistosomiasis (squamous cell carcinoma in endemic areas), bladder stones
  • Cyclophosphamide exposure
  • Pelvic radiation
  • Older age, male sex, Caucasian race
  • Lynch syndrome (HNPCC), hereditary retinoblastoma

Pathophysiology

Carcinogens are concentrated in urine and have prolonged contact with the urothelium. Mutations accumulate in oncogenes (FGFR3 — papillary low-grade tumors) and tumor suppressors (TP53, RB1 — high-grade and muscle-invasive). Field cancerization explains multifocal and recurrent disease throughout the urothelium (ureters, renal pelvis, urethra). NMIBC tumors are slow-growing and recurrent but rarely metastasize; MIBC has rapid progression and metastatic potential.

Clinical presentation

Symptoms

  • Painless gross hematuria — most common presenting symptom (~80%); intermittent
  • Microscopic hematuria (often detected on routine UA)
  • Irritative voiding symptoms — dysuria, frequency, urgency (more common with CIS)
  • Pelvic or back pain (advanced disease)
  • Constitutional symptoms — weight loss, fatigue, anorexia (advanced/metastatic)
  • Symptoms of metastatic disease — bone pain, dyspnea, lymphedema

Signs / physical exam

  • Often unremarkable physical exam in localized disease
  • Suprapubic mass or tenderness in advanced disease
  • Bimanual examination under anesthesia for staging
  • Lymphadenopathy, hepatomegaly, lower extremity edema in metastatic disease
  • Pallor with chronic blood loss anemia

Classic findings

Older smoker with painless gross hematuria — bladder cancer until proven otherwise; warrants cystoscopy.

Differential diagnosis

  • UTI with hematuria — Dysuria, frequency, fever; positive culture; resolves with antibiotics
  • Nephrolithiasis — Colicky flank pain, gross hematuria, stone on CT
  • Renal cell carcinoma — Kidney mass on imaging rather than bladder lesion
  • Upper tract urothelial carcinoma — Filling defect in renal pelvis or ureter; same risk factors; treated with ureteroscopy or nephroureterectomy
  • Benign prostatic hyperplasia — Older men with obstructive symptoms; gross hematuria less common but possible
  • Prostate cancer — Elevated PSA, abnormal DRE; hematuria less typical
  • Interstitial cystitis / radiation cystitis — Chronic pelvic pain, urgency without infection; biopsy distinguishes
  • Glomerular hematuria — Dysmorphic RBCs, RBC casts, proteinuria; nephrology workup

Diagnostic workup

Diagnostic criteria

Definitive diagnosis requires cystoscopic biopsy with histologic confirmation. Transurethral resection of bladder tumor (TURBT) provides both diagnosis and initial treatment, with muscularis propria sampling required to stage T category.

Labs

  • Urinalysis with microscopy — confirms hematuria; rule out infection (urine culture)
  • Urine cytology — useful for high-grade tumors and CIS; low sensitivity for low-grade (~40%)
  • Urine tumor markers (NMP22, BTA) — adjunct, not replacement for cystoscopy
  • BMP, CBC, LFTs

Imaging

  • Cystoscopy — gold standard diagnostic procedure; allows direct visualization and biopsy
  • CT urography with multi-phase imaging — evaluates upper tract (5% of urothelial cancers involve renal pelvis/ureters)
  • MR urography — alternative if contrast contraindicated
  • MRI pelvis for staging muscle invasion
  • CT chest/abdomen/pelvis for staging in MIBC
  • Bone scan or PET if metastasis suspected

Diagnostic algorithm

StageDescriptionStandard Treatment
TaNon-invasive papillary, low or high gradeTURBT ± intravesical therapy
Tis (CIS)Flat, high-grade in situTURBT + intravesical BCG
T1Invades lamina propriaTURBT + BCG (or cystectomy if high-risk)
T2Invades muscularis propriaRadical cystectomy ± neoadjuvant chemo
T3Invades perivesical tissueRadical cystectomy + neoadjuvant chemo
T4Invades adjacent organsChemo + cystectomy or chemoradiation
N+/M+Lymph node or distant metastasisSystemic therapy (chemo + immunotherapy)
Bladder cancer staging (TNM) and standard treatment approach by stage.

Treatment

First-line

  • Non-muscle invasive bladder cancer (NMIBC; Ta, T1, Tis):
  • Transurethral resection of bladder tumor (TURBT) — complete excision with muscularis propria sample
  • Single intravesical chemotherapy (mitomycin C or gemcitabine) within 24 hours of TURBT — reduces recurrence
  • Intravesical BCG (Bacillus Calmette-Guérin) induction + maintenance — for high-risk NMIBC (high-grade T1, CIS, recurrent)
  • Surveillance cystoscopy every 3 months × 2 years, then every 6 months × 2 years, then annually
  • Muscle-invasive bladder cancer (MIBC; T2+):
  • Radical cystectomy with bilateral pelvic lymph node dissection + urinary diversion (ileal conduit or neobladder)
  • Neoadjuvant cisplatin-based chemotherapy (e.g., dose-dense MVAC or gemcitabine/cisplatin) — improves overall survival, given before cystectomy
  • Bladder-sparing tri-modality therapy — maximal TURBT + chemoradiation — for selected patients (small tumor, no CIS, good function)
  • Metastatic disease:
  • Platinum-based chemotherapy (gemcitabine/cisplatin) if cisplatin-eligible
  • Immune checkpoint inhibitors (pembrolizumab, nivolumab, atezolizumab, avelumab) — maintenance or after platinum failure
  • Enfortumab vedotin + pembrolizumab — first-line for cisplatin-ineligible or platinum-resistant

Second-line / adjunct

  • BCG-unresponsive NMIBC: pembrolizumab, nadofaragene firadenovec, or radical cystectomy
  • FGFR3-mutant urothelial carcinoma: erdafitinib (FGFR inhibitor)
  • HER2-expressing: trastuzumab deruxtecan
  • Palliative measures for hematuria: cystoscopy with fulguration, palliative cystectomy, embolization
  • Smoking cessation — improves outcomes and reduces recurrence
  • Genitourinary survivorship: surveillance for second urothelial cancers (upper tract)

Complications

  • Recurrence (NMIBC ~50-70% recurrence rate)
  • Progression from NMIBC to MIBC
  • Metastasis (lymph nodes, lung, liver, bone)
  • Hydronephrosis from ureteral obstruction
  • Cystectomy complications: bleeding, infection, urinary diversion problems, ileus, sexual/urinary dysfunction
  • BCG complications: cystitis, BCG sepsis (rare, requires anti-TB therapy)
  • Chemotherapy/immunotherapy toxicities

PANCE pearls

  • Painless gross hematuria in an adult >35-40 years requires evaluation with cystoscopy and upper tract imaging — even if it resolves.
  • Smoking is the single greatest risk factor; counsel cessation as part of treatment (improves outcomes).
  • BCG is a live attenuated tuberculosis vaccine that activates local immune response; works for high-risk NMIBC and CIS but not muscle-invasive disease.
  • Schistosoma haematobium causes squamous cell bladder cancer in endemic areas (Egypt, Sub-Saharan Africa).
  • Field cancerization: urothelial carcinoma can arise anywhere in the urothelium — always evaluate upper tract (renal pelvis, ureters) in addition to bladder.
  • Microscopic hematuria evaluation per AUA: CT urography + cystoscopy if risk factors (smoking, age, occupational exposure); risk-stratified approach for low-risk patients.

References

  • AUA/SUO 2020 — Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline (Chang et al., J Urol 2020)
  • AUA/ASCO/ASTRO/SUO 2017 — Treatment of Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline
  • AUA 2020 Hematuria — Microhematuria: AUA/SUFU Guideline (Barocas et al., J Urol 2020)
  • NCCN 2024 — NCCN Clinical Practice Guidelines in Oncology: Bladder Cancer Version 2024

Practice Renal/Urology questions on FirstPassPA

Turn this outline into retention. 6,500+ board-style questions with an AI tutor that explains every answer — free to start, no card required.

Answer the 2 free questions above → Get today's free question →

Related Renal/Urology diagnoses

Acute Kidney Injury (AKI)Chronic Kidney Disease (CKD)End-Stage Renal Disease and DialysisNephrotic SyndromeNephritic SyndromeIgA NephropathyAcute Tubular Necrosis (ATN)Acute Interstitial Nephritis (AIN)Post-Streptococcal Glomerulonephritis (PSGN)Autosomal Dominant Polycystic Kidney Disease (ADPKD)Urolithiasis (Kidney Stones)Acute Cystitis (Uncomplicated UTI)Acute PyelonephritisRenal Cell Carcinoma (RCC)

Differentials & related conditions

Benign Prostatic Hyperplasia (BPH)

Educational use only. This outline is a study aid for PA students and is not medical advice or a substitute for clinical judgment. FirstPassPA is an independent study tool and is not affiliated with, endorsed by, or sponsored by NCCPA or PAEA. PANCE® and PANRE® are registered trademarks of the National Commission on Certification of Physician Assistants; End of Rotation™ is a program of the Physician Assistant Education Association.